1. Cnop M, Vidal J, Hull RL, et al. Progressive loss of {beta}-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. March 1, 2007; 30(3):677-82.

2. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. UKPDS 16. Diabetes. November 1, 1995; 44(11):1249-58.

3. Inzucchi SE. Oral Antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc January 16, 2002; 287(3):360-72.

4. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. April 1,2001; 24(4):758-67.

5. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. November 1, 2003; 26(11):3080-6.

6. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. February 1, 2005; 28(2):260-5.

7. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 2006; 8(1):58-66.

8. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. August 17, 1999; 131(4):281-303.

9. Stern M, Gonzalez C, Mitchell B, Villalpando E, Haffner S, Hazuda H. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes. April 1, 1992; 41(4): 484-92.

10. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity. J Nutr February 1, 2001; 131(2):354S-60.

11. Utzschneider KM, Prigeon RL, Carr DB, et al. Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care. February 1, 2006; 29(2):356-62.

12. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia January 1, 2003; V46(1):3-19.

13. Saad M, Knowler W, Pettitt D, Nelson R, Mott D, Bennett P. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med December 8, 1988; 319(23):1500-6.

14. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest September 15, 1999; 104(6):787-94.

15. Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes February 1, 2002; 51(90001):S262-4.

16. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes January 1, 2004; 53(1):160-5.

17. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic {beta}-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes September 1, 2002; 51(9):2796-803.

18. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet September 12, 1998; 352(9131):854-65.

19. Matthews D, Cull C, Stratton I, Holman R, Turner R. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med April 1998; 15(4):297-303.

20. Leahy J, Weir G. Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes February 1, 1988; 37(2):217-22.

21. Leibowitz G, Yuli M, Donath M, et al. Beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes February 1, 2001; 50(90001):S113-7.

22. McGarry JD. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes January 1, 2002; 51(1):7-18.

23. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2002/12/30 2002; 1585(2-3):202-12.

24. Andrews W, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes July 1, 1984; 33(7):634-42.

25. Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes March 1, 1985; 34(3):222-34.

26. Henry R, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber H. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care January 1, 1993; 16(1):21-31.

27. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes February 1, 2002; 51(2):462-8.

28. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care September 1, 1997; 20(9):1353-6.

29. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes May 1, 1996; 45(5):633-8.

30. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. The Am J Med 2000/4/17 2000; 108(6, Supplement 1):9-14.

31. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes Dec 1988; 37(12):1595-607.

32. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama: the Journal of the American Medical Association. May 2001; 285(19): 2486-97.

33. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care March 1, 1979; 2(2):131-41.

34. Haffner SM, Hanley AJG. Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation April 30, 2002; 105(17): 2008-9.

35. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352(9131):837-53.

36. Malmberg K, Ryden L, Hamstent A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J September 1, 1996; 17(9):1337-44.

37. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation May 25, 1999; 99(20):2626-32.

38. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol Feb 1962; 9:166-81.

39. Sodi-Pallares D, Bisteni A, Medrano GA, Testelli MR, De Micheli A. The polarizing treatment of acute myocardial infarction. Possibility of its use in other cardiovascular conditions. Dis Chest Apr 1963; 43:424-32.

40. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet Jan 15 1994; 343(8890):155-8.

41. Opie L. Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium? The Lancet 1999/3/6 1999; 353(9155):768-9.

42. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J April 1, 2005; 26(7):650-61.

43. Bogardus C, Taskinen M, Zawadzki J, Lillioja S, Mott D, Howard B. Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. Diabetes January 1, 1986; 35(1):1-5.

44. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2007; 9(3):386-93.

45. Yki-Jarvinen H, Helve E, Sane T, Nurjhan N, Taskinen MR. Insulin inhibition of overnight glucose production and gluconeogenesis from lactate in NIDDM. Am J Physiol Jun 1989; 256(6 Pt 1):E732-9.

46. Franssila-Kallunki A, Groop L. Factors associated with basal metabolic rate in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. Oct 1992; 35(10):962-6.

47. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med Aug 31 1995; 333(9):550-4.

48. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia Apr 1999; 42(4):406-12.

49. Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. Dec 1997; 82(12):4037-43.

50. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. Jan 1998; 6(1):47-53.

51. Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. INITIATE (INITiate Insulin by Aggressive Titration and Education). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care Mar 23, 2007; 30:1364-69.

52. Billingham MS, Milles JJ, Bailey CJ, Hall RA. Lipoprotein subfraction composition in non-insulin-dependent diabetes treated by diet, sulphonylurea, and insulin. Metabolism Sep 1989; 38(9):850-7.

53. Rivellese AA, Patti L, Romano G, et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab Nov 2000; 85(11):4188-92.

54. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care Jun 1995; 18(6):843-51.

55. Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: veterans affairs cooperative study in type ii diabetes mellitus. Arch Intern Med Dec 7-21 1998; 158(22):2485-90.

56. De Leeuw I, Vague P, Selam J, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diab Obes Metab 2005; 7:73-82.

57. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res Nov 2005; 37(11):702-7.

58. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care Mar 2007; 30(3):579-85.

59. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care Oct 2004; 27(10):2356-62.

60. Heise T, Nosek L, Ronn BB, et al. Lower Within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes June 1, 2004; 53(6): 1614-20.

61. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care Feb 2002; 25(2):330-6.

62. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med September 30, 1993; 329(14):977-86.

63. Boyle PJ, Cryer PE. Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol. Mar 1991; 260(3 Pt 1):E395-402.

64. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia Oct 1999; 42(10):1151-67.

65. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet Sep 1 2001; 358(9283):739-46.

66. Skyler JS. Diabetes Mellitus, Types I and II. Humes HD, ed. Kelley's Textbook of Internal Medicine. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.

67. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes Sep 2005; 113(8):435-43.

68. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes May 2005; 113(5):292-7.

69. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes Mar 1994; 43(3):396-402.

70. Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med Jul 17 1997; 337(3):176-83.

71. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol May 1999; 55(3):199-203.

72. Gammeltoft S, Hansen BF, Dideriksen L, et al. Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Investig Drugs. Sep 1999; 8(9):1431-42.

73. Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced [beta]-cell protective action. Biochemical and Biophysical Research Communications 2003; 310(3):852-9.

74. Anderson JH Jr., Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes Feb 1997; 46(2):265-70.

75. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. May 2000; 23(5):583-8.

76. Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia. Jan 1995; 38(1): 106-11.

77. Torlone E, Pampanelli S, Lalli C, et al. Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care Sep 1996; 19(9):945-52.

78. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med Jul 1998; 15(7):592-600.

79. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med Mar 2000; 17(3):209-14.

80. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care Oct 1998; 21 (10):1726-31.

81. Heinemann L. Hypoglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications Mar-Apr 1999; 13(2):105-14.

82. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care Nov 1998; 21(11):1904-9.

83. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med Nov 2000; 17(11):762-70.

84. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care Oct 1999; 22(10):1607-11.

85. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care Mar 1999; 22(3):468-77.

86. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med Apr 1999; 16(4):319-24.

87. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes Mar 1997; 46(3):440-3.

88. Melki V, Renard E, Lassmann-Vague V, et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care Jun 1998; 21(6): 977-82.

89. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care May 1999; 22(5):784-8.

90. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med Jan 1996; 13(1):47-52.

91. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr Jul 2000; 159(7):483-8.

92. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care Jun 2000; 23(6):813-9.

93. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 1, 2000; 49(12):2142-8.

94. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care May 2000; 23(5):644-9.

95. Scholtz HE, Pretorius SG, Wessels DH, Becker RHA. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005; 48(10):1988-95.

96. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care January 1, 2005; 28(1):10-4.

Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med Jan 2006; 23(1):46-52. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med Aug 2006; 23(8):879-86. Karaguzel G, Satilmis A, Akcurin S, Bircan I. Comparison of breakfast and bedtime administration of insulin glargine in children and adolescents with Type 1 diabetes. Diabetes Res Clin Pract Oct 2006; 74(1):15-20.

Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care Aug 2000; 23(8):1137-42.

Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care Feb 2000; 23(2):157-62.

Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care May 2000; 23(5):639-43.

Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care Nov 2000; 23(11):1666-71.

Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care Apr 2000; 23(4):557-9.

Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care Aug 2000; 23(8):1130-6.

Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care Apr 2001; 24(4):631-6.

Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia Mar 1996; 39(3):281-8.

Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med Apr 1999; 16(4):332-8.

Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type

1 diabetic subjects on basal-bolus therapy. Diabetes Care Feb 2001; 24(2):296-301.

Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with nph insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care June 1, 2006; 29(6):1269-74.

Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with nph insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther May 2004; 26(5):724-36.

Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther Oct 2004; 6(5): 579-88.

Pieber TR, Treichel H-C, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabetic Medicine March 22, 2007; 24: 635-42.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 2006; 55(Supplement):325-OR. D'Eliseo P, Blaauw J, Milicevic Z, Wyatt J, Ignaut DA, Malone JK. Patient acceptability of a new 3.0 ml pre-filled insulin pen. Curr Med Res Opin 2000; 16(2):125-33.

Gall MA, Mathiesen ER, Skott P, et al. Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. Diabetes Res Jun 1989; 11(2):97-101.

Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev Feb 1 1999; 35(2-3):235-47. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care Sep 2000; 23(9):1343-7.

Weiss SR, Cheng S-L, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med October 27, 2003; 163(19): 2277-82.

121. Hausmann M, Dellweg S, Osborn C, et al. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes, Obesity and Metabolism 2006; 8(5):574-80.

122. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, on behalf of the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care August 1, 2006; 29(8):1818-25.

123. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med Oct 18 2005; 143(8):549-58.

124. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes May 1999; 48(5):1198-214.

125. Doar JW, Thompson ME, Wilde CE, Sewell PF. Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus. Br Med J Feb 28 1976; 1(6008): 498-500.

126. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes Mar 1998; 47(3):345-51.

127. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res Jun 1995; 27(6):263-6.

128. Perfetti R, Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. Trends Endocrinol Metab Aug 2000; 11(6):218-23.

129. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 368(9548):1696-705.

130. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med Mar 26 1998; 338(13):867-72.

131. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care Jan 1999; 22(1):33-7.

132. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med Jul 2 2002; 137(1): 25-33.

133. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes Jul 2002; 51(7):2074-81.

134. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med November 3, 1994; 331(18): 1188-93.

135. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes May 2000; 49(5):827-31.

136. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001; 52:239-57.

137. Frias JP, Yu JG, Kruszynska YT, Olefsky JM. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care Jan 2000; 23(1):64-9.

138. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med Feb 1 1998; 128(3):176-85.

139. Goke B, Herrmann-Rinke C. The evolving role of alpha-glucosidase inhibitors. Diabetes Metab Rev Sep 1998; 14 Suppl 1:S31-8.

140. Lebovitz HE. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors. Drugs 1992; 44 Suppl 3:21-8.

141. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am Sep 1997; 26(3): 539-51.

142. Holman RR, Steemson J, Turner RC. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med Sep-Oct 1987; 4(5):457-62.

143. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care Oct 1989; 12(9): 623-9.

144. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes Aug 2000; 49(8):1367-73.

145. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes Feb 1995; 44(2):165-72.

146. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70 /30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care Jul 1998; 21(7):1052-7.

147. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care Dec 2003; 26(12):3273-9.

148. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44(2):107-12.

149. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med Aug 3 1999; 131(3):182-8.

150. Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial. Diabet Med Dec 1998; 15(12):997-1002.

151. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care May 1998; 21(5):701-5.

152. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med Mar 26 1998; 338(13):861-6.

153. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care Jul 2001; 24(7):1226-32.

154. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract May 2002; 56(4):251-7.

155. Yki-Jarvinen H, Ryysky L, Nikkila K. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999; 130:389-96.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment